1267 related articles for article (PubMed ID: 19874350)
1. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
2. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
Viera MH; Perez OA; Patel JK; Jones I; Berman B
Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
[TBL] [Abstract][Full Text] [Related]
3. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
Wolf R; Matz H; Marcos B; Orion E
Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
[TBL] [Abstract][Full Text] [Related]
4. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
5. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
[TBL] [Abstract][Full Text] [Related]
6. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
8. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.
Hosaka H; Ohtoshi S; Nakada T; Iijima M
J Dermatol; 2010 May; 37(5):407-12. PubMed ID: 20536645
[TBL] [Abstract][Full Text] [Related]
9. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
10. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
[TBL] [Abstract][Full Text] [Related]
11. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.
Gau SS; Chao PF; Lin YJ; Chang CJ; Gau CS
J Clin Psychopharmacol; 2008 Oct; 28(5):509-17. PubMed ID: 18794645
[TBL] [Abstract][Full Text] [Related]
12. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions.
Hirahara K; Kano Y; Mitsuyama Y; Takahashi R; Kimishima M; Shiohara T
Clin Exp Dermatol; 2010 Dec; 35(8):863-8. PubMed ID: 20456395
[TBL] [Abstract][Full Text] [Related]
13. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
Halevy S
Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
[TBL] [Abstract][Full Text] [Related]
14. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
15. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hung CC; Liu WC; Kuo MC; Lee CH; Hwang SJ; Chen HC
Am J Nephrol; 2009; 29(6):633-8. PubMed ID: 19155617
[TBL] [Abstract][Full Text] [Related]
16. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
[TBL] [Abstract][Full Text] [Related]
17. [Erythema multiforme vs. Stevens-Johnson syndrome and toxic epidermal necrolysis: an important diagnostic distinction].
Rabelink NM; Brakman M; Maartense E; Bril H; Bakker-Wensveen CA; Bavinck JN
Ned Tijdschr Geneeskd; 2003 Oct; 147(43):2089-94. PubMed ID: 14619195
[TBL] [Abstract][Full Text] [Related]
18. Serious and life-threatening drug eruptions.
Manders SM
Am Fam Physician; 1995 Jun; 51(8):1865-72. PubMed ID: 7762478
[TBL] [Abstract][Full Text] [Related]
19. The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity.
Hanafusa T; Azukizawa H; Matsumura S; Katayama I
J Dermatol Sci; 2012 Mar; 65(3):213-9. PubMed ID: 22226608
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.
Sotozono C; Ueta M; Koizumi N; Inatomi T; Shirakata Y; Ikezawa Z; Hashimoto K; Kinoshita S
Ophthalmology; 2009 Apr; 116(4):685-90. PubMed ID: 19243825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]